Registry of Lobbyists

Registration - In-house Organization

Innovative Medicines Canada / Médicaments novateurs Canada / Bettina Hamelin, President

Registration Information

In-house Organization name: Innovative Medicines Canada / Médicaments novateurs Canada
Previous in-house organization names
Responsible Officer Name: Bettina Hamelin, President 
Responsible Officer Change History
Initial registration start date: 2004-08-19
Registration status: Active
Registration Number: 957857-371

Associated Communications

Total Number of Communication Reports: 963

Monthly communication reports in the last 6 months: 43

Version 9 of 117 (2008-05-14 to 2008-08-08)

Version 9 of 117 (2008-05-14 to 2008-08-08) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Organization Information

Organization: Canada's Research-Based Pharmaceutical Companies
55 Metcalfe St.
Suite 1220
Ottawa, ON  K1P 6L5
Canada
Telephone number: 613-236-0455  Ext.: 425
Fax number: 613-236-6756  
Responsible officer name and position during the period of this registration: RUSSELL WILLIAMS, PRESIDENT  
 
Description of the organization's activities: Canada's Research-Based Pharmaceutical Companies (Rx&D) is the industry association of Canada's research-based pharmaceutical industry. The companies that make up the membership of Rx&D are engaged in the research and development, production, marketing, and servicing of prescription and non-prescription pharmaceutical products. Rx&D members employ more than 22,000 people across Canada. Comprised of companies of all sizes, Rx&D's membership reflects the international scope of the pharmaceutical industry and includes the Canadian operations of domestic firms. As well as those with headquarters in other countries, Rx&D membership is currently made up of approximately 50 member companies.
Organization's membership or classes of membership: (a) Full Membership: Full membership is open to innovative pharmaceutical Persons which research, develop, manufacture and/or distribute pharmaceutical prescription preparations under their own labels in Canada. (b) Biopharmaceutical Membership: Biopharmaceutical membership is open to Persons who are engaged, for profit, in research and development of pharmaceutical products and/or biopharmaceutical health care products with the aim of producing, manufacturing or distributing the same under its own label. (c) Medical Research Affiliate Membership: Medical research affiliate membership is open to non-profit organizations engaged in research which have a relationship or are connected with hospitals, universities, research institutes, recognized health/disease organizations, or divisions or units thereof, whose membership, in the determination of the Board, would be consistent with the objects of the Association and would enhance the ability of the Association to attain such objects, and who are engaged in health research. (d) Associate Membership: Associate membership is open to Persons who do not qualify under any of the foregoing membership categories and whose membership, in the determination of the Board, would be consistent with the objects of the Association and would enhance the ability of the Association to attain such objects (»Associate Members«). Without limiting the generality of the foregoing, Associate Members may include contract research organizations, contract manufacturing organizations and clinical research organizations who supply goods and/or services to Full Members or Biopharmaceutical Members and other stakeholder groups.
 
Was the organization funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Organization

Name: Declan Hamill
Position title: Vice-President, Legal Affairs and Intellectual Property Policy
Public offices held: Yes
 
Name: Normand Laberge
Position title: Vice President, Federal Affairs and Federal, Provincial and Territorial Relations
Public offices held: No
 
Name: Jacques Lefebvre
Position title: Vice-President, Strategic Affairs & Communications
Public offices held: Yes
 
Name: Ivan Vrana
Position title: Director, Federal, Provincial & Territorial Relations
Public offices held: Yes
 
Name: Russell Williams
Position title: President
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Agriculture and Agri-Food Canada (AAFC), Canadian Institutes of Health Research (CIHR), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Citizenship and Immigration Canada, Competition Tribunal (CT), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources and Social Development Canada (HRSDC), Industry Canada, Justice Canada (JC), Members of the House of Commons, National Defence (DND), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Office of the Auditor General, Office of the Information and Privacy Commissioner (OIPC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Works and Government Services Canada, Revenue Canada (RC), Senate of Canada, Solicitor General Canada (SGC), Statistics Canada (StatCan), Transport Canada (TC), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Affairs, Agriculture, Arts and Culture, Broadcasting, Constitutional Issues, Consumer Issues, Defence, Education, Employment and Training, Energy, Environment, Financial Institutions, Fisheries, Forestry, Government Procurement, Health, Immigration, Industry, Infrastructure, Intellectual Property, Internal Trade, International Relations, International Trade, Justice and Law Enforcement, Labour, Mining, Regional Development, Science and Technology, Small Business, Sports, Taxation and Finance, Telecommunications, Tourism, Transportation
 
Subject Matter: Retrospective: Industry Canada: political/bureaucrat - innovation strategy, Patented Medicines (PM) Notice of Compliance (NOC) regulations, cross-border trade, budget, issues affecting health and pharmaceutical industries, and biotechnology. Health Canada: innovation strategy, PM (NOC) regulations, cross-border trade, international aid programs.
Subject Matter: Prospective: Treasury Board: Smart Regulations Industry Canada: innovation issues, PM (NOC) regulations, pharmaceutical and biotechnology R&D issues, smart regulations, cross-border trade, patent policy. Health Canada: drug safety, data regulations, innovation issues, cross border trade, drug approval, counterfeit drugs, and national pharmaceutical strategy. Foreign Affairs: ongoing international issues, cross-border trade. Finance: Budget/budget update.
 

Details Regarding the Identified Subject Matter

Categories Description
Policy or Program Agreement on Trade-Related Aspects of Intellectual Property Rights
Legislative Proposal Budgets/Budget updates
Legislative Proposal Canada's Food and Consumer Safety Action Plan (Food and Drugs Act)
Policy or Program Canadian Agency for Drugs and Technologies in Health
Policy or Program Canadian and international trade agreements and negotiations related to Intellectual Property impacting the biopharmaceutical industry
Legislative Proposal Canadian Environmental Protection Act
Policy or Program Canadian Institutes of Health Research (CIHR) Clinical Research Initiative
Policy or Program Common Drug Review
Policy or Program Counterfeit drugs
Policy or Program Cross-Border Trade
Policy or Program Drug approval
Policy or Program Drug safety
Legislative Proposal Federal Accountability Act
Regulation Food and Drug Regulations (Data Protection)
Policy or Program Free trade treaty negotiations Policy or program intellectual property policy
Policy or Program General Agreement on Tariffs and Trade
Policy or Program Innovation policy related to the Canadian biopharmaceutical industry
Policy or Program Intergovernmental Working Group on access to medicines
Regulation Lobbyist Registration Regulations
Policy or Program National Pharmaceutical Strategy
Regulation New Substances Notification Regulations
Policy or Program North American Free Trade Agreement
Legislative Proposal Patent Act
Regulation Patented Medicines (Notice of Compliance) Regulations
Regulation Patented Medicines Regulations, 1994
Policy or Program Pharmaceutical pricing policy issues
Policy or Program Post-market surveillance of pharmaceuticals
Policy or Program Progressive licensing framework
Policy or Program Scientific Research and Educational Design (SR&ED) Tax Credit
Regulation Smart Regulations
Policy or Program Subsequent entry biologics
Policy or Program Taxation policy related to pharmaceuticals
Policy or Program The government's Science and Technology strategy
Policy or Program World Health Organization issues related to pharmaceuticals

Government institutions added through a communication report: House of Commons View



Date Modified: